Enhancing antitumor immunity perioperatively a matter of timing, cooperation, and specificity

American Journal of Respiratory Cell and Molecular Biology

Volumn 28, Issue 5, 2003, Pages 541-545

  Curtis, Jeffrey L ^a   Punturieri, Antonello ^b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGIC AGENT; INTERLEUKIN 12; LIPOPROTEIN; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; LUNG METASTASIS; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; REVIEW; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; DROSOPHILA PROTEINS; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MEMBRANE GLYCOPROTEINS; NEOPLASMS; OLIGOPEPTIDES; PERIOPERATIVE CARE; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS;

EID: 0037732718     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.F266     Document Type: Review

References (61)

1. Pardoll, D. M. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:227-238.
2. Rosenberg, S. A. 2001. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250:462-475.
3. Coley, W. B. 1893. The treatment of malignant tumors by repeated inoculation of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105:487-511.
4. Azuma, I., and T. Seya. 2001. Development of immunoadjuvants for immunotherapy of cancer. Int. Immunopharmacol, 1:1249-1259.
5. Shingu, K., C. Krushcinski, A. Lürhmann, K. Grote, T. Tschernig, S. von Hörsten, and R. Pabst. 2003. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am. J. Respir. Cell Mol. Biol. 28:316-321.
6. Shingu, K., A. Helfritz, S. Kuhlmann, M. Zielinska-Skowronek, R. Jacobs, R. E. Schmidt, R. Pabst, and S. von Horsten. 2002. Kinetics of the early recruitment of leukocyte subsets at the sites of tumor cells in the lungs: natural killer (NK) cells rapidly attract monocytes but not lymphocytes in the surveillance of micrometastasis. Int. J. Cancer 99:74-81.
7. Takeuchi, O., A. Kaufmann, K. Grote, T. Kawai, K. Hoshino, M. Morr, P. F. Mühlradt, and S. Akira. 2000. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 164:554-557.
8. Glaves, D. 1983. Correlation between circulating cancer cells and incidence of metastases. Br. J. Cancer 48:665-673.
9. Patel, H., N. Le Marer, R. Q. Wharton, Z. A. Khan, R. Araia, C. Glover, M. M. Henry, and T. G. Allen-Mersh. 2002. Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann. Surg. 235:226-231.
10. Yamashita, J., A. Matsuo, Y. Kurusu, T. Saishoji, N. Hayashi, and M. Ogawa. 2002. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J. Thorac. Cardiovasc. Surg. 124:299-305.
11. Mori, M., K. Mimori, H. Ueo, N. Karimine, G. F. Barnard, K. Sugimachi, and T. Akiyoshi. 1996. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int. J. Cancer 68:739-743.
12. Yamaguchi, K., Y. Takagi, S. Aoki, M. Futamura, and S. Saji. 2000. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 232:58-65.
13. Miyazono, F., S. Natsugoe, S. Takao, K. Tokuda, F. Kijima, K. Aridome, S. Hokita, M. Baba, Y. Eizuru, and T. Aikou. 2001. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann. Surg. 233:189-194.
14. Garcia-Olmo, D., J. Ontanon, D. C. Garcia-Olmo, M. Vallejo, and J. Cifuentes. 1999. Experimental evidence does not support use of the "no-touch" isolation technique in colorectal cancer. Dis. Colon Rectum 42:1449-1456.
15. Hayashi, N., H. Egami, M. Kai, Y. Kurusu, S. Takano, and M. Ogawa. 1999. No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer. Surgery 125:369-374.
16. Bessa, X., J. I. Elizalde, L. Boix, V. Pinol, A. M. Lacy, J. Salo, J. M. Pique, and A. Castells. 2001. Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 120:1084-1092.
17. Shakhar, G., and S. Ben-Eliyahu. 1998. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 160:3251-3258.
18. Page, G. G., W. P. Blakely, and S. Ben-Eliyahu. 2001. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 90:191-199.
19. Ben-Eliyahu, S., G. G. Page, R. Yirmiya, and G. Shakhar. 1999. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int. J. Cancer 80:880-888.
20. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2:957-965.
21. Trinchieri, G. 1995. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin. Immunol. 7:83-88.
22. Herberman, R. B. 2002. Cancer immunotherapy with natural killer cells. Semin. Oncol. 29:27-30.
23. Colucci, F., J. P. Di Santo, and P. J. Leibson. 2002. Natural killer cell activation in mice and men: different triggers for similar weapons? Nat. Immunol. 3:807-813.
24. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2:850-861.
25. Long, E. O. 2002. Tumor cell recognition by natural killer cells. Semin. Cancer Biol. 12:57-61.
26. Kim, S., K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 97:2731-2736.
27. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, M. F. Martelli, and A. Velardi. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100.
28. Gordon, S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
29. Klimp, A. H., E. G. de Vries, G. L. Scherphof, and T. Daemen. 2002. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 44:143-161.
30. Medzhitov, R., and C. A. Janeway, Jr. 1997. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91:295-298.
31. Barton, G. M., and R. Medzhitov. 2002. Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 270:81-92.
32. Schwandner, R., R. Dziarski, H. Wesche, M. Rothe, and C. J. Kirschning. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274:17406-17409.
33. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169:10-14.
34. Takeuchi, O., T. Kawai, P. F. Mühlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13:933-940.
35. Davis, I. D. 2000. An overview of cancer immunotherapy. Immunol. Cell Biol. 78:179-195.
36. Persing, D. H., R. N. Coler, M. J. Lacy, D. A. Johnson, J. R. Baldridge, R. M. Hershberg, and S. G. Reed. 2002. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10:S32-S37.
37. Yu, Z., and N. P. Restifo. 2002. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 110:289-294.
38. Loewenstein, J., S. Rottem, and R. Gallily. 1983. Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas. Cell. Immunol. 77:290-297.
39. Kostyal, D. A., G. H. Butler, and D. H. Beezhold. 1994. A 48-kilodalton Mycoplasma fermentans membrane protein induces cytokine secretion by human monocytes. Infect. Immun. 62:3793-3800.
40. Rawadi, G., and S. Roman-Roman. 1996. Mycoplasma membrane lipoproteins induced proinflammatory cytokines by a mechanism distinct from that of lipopolysaccharide. Infect. Immun. 64:637-643.
41. Calcutt, M. J., M. F. Kim, A. B. Karpas, P. F. Mühlradt, and K. S. Wise. 1999. Differential posttranslational processing confers intraspecies variation of a major surface lipoprotein and a macrophage-activating lipopeptide of Mycoplasma fermentans. Infect. Immun. 67:760-771.
42. Seya, T., and M. Matsumoto. 2002. A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2. Int. J. Biochem. Cell Biol. 34:901-906.
43. Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. D. Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274:33419-33425.
44. Toshchakov, V., B. W. Jones, P. Y. Perera, K. Thomas, M. J. Cody, S. Zhang, B. R. Williams, J. Major, T. A. Hamilton, M. J. Fenton, and S. N. Vogel. 2002. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3:392-398.
45. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549-555.
46. Belperio, J. A., M. P. Keane, D. A. Arenberg, C. L. Addison, J. E. Ehlert, M. D. Burdick, and R. M. Strieter. 2000. CXC chemokines in angiogenesis. J. Leukoc. Biol. 68:1-8.
47. Kono, K., F. Salazar-Onfray, M. Petersson, J. Hansson, G. Masucci, K. Wasserman, T. Nakazawa, P. Anderson, and R. Kiessling. 1996. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26:1308-1313.
48. Hansson, M., A. Asea, U. Ersson, S. Hermodsson, and K. Hellstrand. 1996. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol. 156:42-47.
49. Bingle, L., N. J. Brown, and C. E. Lewis. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196:254-265.
50. Savill, J., and V. Fadok. 2000. Corpse clearance defines the meaning of cell death. Nature 407:784-788.
51. Albert, M. L., S. F. Pearce, L. M. Francisco, B. Sauter, P. Roy, R. L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359-1368.
52. 2, and PAF. J. Clin. Invest. 101:890-898.
53. Freire-de-Lima, C. G., D. O. Nacimento, M. B. P. Soares, P. T. Bozza, H. C. Castro-Faria-Neto, F. G. de Mello, G. A. DosReis, and M. F. Lopes. 2000. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403:199-203.
54. Hildenbrand, R., C. Jansen, G. Wolf, B. Bohme, S. Berger, G. von Minckwitz, A. Horlin, M. Kaufmann, and H. J. Stutte. 1998. Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Lab. Invest. 78:59-71.
55. Steinman, R. M., S. Turley, I. Mellman, and K. Inaba. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191:411-416.
56. Newman, S. L., J. E. Henson, and P. M. Henson. 1982. Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages. J. Exp. Med. 156:430-442.
57. Hu, B., J. Sonstein, P. J. Christensen, A. Punturieri, and J. L. Curtis. 2000. Deficient in vitro and in vivo phagocytosis of apoptotic T cells by resident murine alveolar macrophages. J. Immunol. 165:2124-2133.
58. van der Brugge-Gamelkorn, G. J., C. D. Dijkstra, and T. Sminia. 1985. Characterization of pulmonary macrophages and bronchus associated lymphoid tissue macrophages of the rat. An enzyme-cytochemical and immuno-cytochemical study. Immunobiol 169:553-562.
59. Scott, L. J., and C. M. Perry. 2000. Tramadol: a review of its use in perioperative pain. Drugs 60:139-176.
60. Gaspani, L., M. Bianchi, E. Limiroli, A. E. Panerai, and P. Sacerdote. 2002. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J. Neuroimmunol. 129:18-24.
61. Dougenis, D., V. Patrinou, K. S. Filos, E. Theodori, K. Vagianos, and A. Maniati. 2001. Blood use in lung resection for carcinoma: perioperative elective anaemia does not compromise the early outcome. Eur. J. Cardiothorac. Surg. 20:372-377.